CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue
Total operating revenue	$ 76,192,000	$ 55,161,000
Operating expenses
Goodwill impairment charges	16,867,000	0
Selling, general and administrative expense	28,830,000	29,806,000
Depreciation and amortization	1,269,000	987,000
Total operating expenses	109,059,000	73,632,000
Loss from operations	(32,867,000)	(18,471,000)
Other non-operating expense (income)
Interest expense	2,650,000	74,000
Interest income	(1,207,000)	0
Change in fair value of derivative warrant liabilities	(143,000)	1,461,000
Change in fair value of earnout liabilities	(752,000)	(39,440,000)
Change in fair value of conversion option derivative liabilities	(3,318,000)	0
Gain on loan forgiveness	0	(183,000)
Other, net	(143,000)	151,000
Total other non-operating income	(2,913,000)	(37,937,000)
(Loss) income before provision for income taxes	(29,954,000)	19,466,000
Income tax expense	(44,000)	(180,000)
Net income (loss)	$ (29,998,000)	$ 19,286,000
Net income (loss) per share attributable to common stockholders:
Basic (in usd per share)	$ (0.33)	$ 0.22
Diluted (in usd per share)	$ (0.33)	$ 0.21
Weighted-average number of shares outstanding:
Basic (in shares)	73,449,132	73,252,365
Diluted (in shares)	73,449,132	76,247,966
Patient services
Revenue
Total operating revenue	$ 50,273,000	$ 35,057,000
Operating expenses
Direct costs	42,814,000	27,378,000
Dispensary
Revenue
Total operating revenue	24,240,000	18,679,000
Operating expenses
Direct costs	19,145,000	15,324,000
Clinical trials & other
Revenue
Total operating revenue	1,679,000	1,425,000
Operating expenses
Direct costs	$ 134,000	$ 137,000